Q32 Bio Inc. (QTTB)
$8.74+4.80%Close
SELLCRISIS · day 31
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $112M
- Beta
- -0.33
- P/E (TTM)
- 2.91
- Short % float
- 72.96%
- Days to cover
- 4.3
- SI change
- +23.8%
- 1W
- +4.42%
- 1M
- -21.26%
- vs SPY 1W
- +4.00%
- vs SPY 1M
- -23.32%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 38
- VALUE
- 45
- GROWTH
- 73
- GARP
- 14
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC46.1%
REV YoY-
ROE76.9%
EPS YoY-
ROA29.2%
GROSS100
OP40
NET63
[VALUATION]
P/E TTM2.91
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B1.08
P/FCF-
EV/EBITDA4.06
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.00
ALTMAN Z-
CURR RATIO20.30
ND/EBITDA-
BETA-0.33
Company news
FAQ
- What is LOPJLB’s current signal on QTTB?
- LOPJLB’s latest quantitative signal on Q32 Bio Inc. (QTTB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is QTTB in?
- Q32 Bio Inc. (QTTB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Q32 Bio Inc. (QTTB) do?
- Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody …